Effects of Lipid-Lowering Therapy with Rosuvastatin on Atherosclerotic Burden in Patients with Chronic Kidney Disease

Abstract

Objective Although previous studies suggest that treatment

A Trial of Pitavastatin Versus Rosuvastatin for Dyslipidemia in Chronic Kidney Disease

“…; this proposal is in line with the suggested mechanisms of renoprotection mentioned above [23][24][25] . Many available clinical data also suggest the renoprotective effects of statins, thereby supporting the validity of results from the present study [26][27][28] . For increased accuracy in eGFR measurement, this study used a mean eGFR value from two eGFR values calculated using CysC and S-Cr.…”

Atorvastatin exhibits anti-inflammatory and anti-oxidant properties in adjuvant-induced monoarthritis

“…Statins are cholesterol-lowering drugs commonly prescribed to patients with dyslipidemia, and their use has been shown to reduce cardiovascular morbidity and mortality (Downs et al 1998;Sawara et al 2008;Nasu et al 2009). The beneficial effects of statins have been attributed to their ability to suppress inflammation, modulate endothelial function, immune response, and to exhibit antioxidant property (Blum and Shamburek 2009;Lansberg 2009;Shaw et al 2009).…”

Current perspectives on rosuvastatin

“…Rosuvastatin treatment was significantly associated with a 26.6% reduction in left CIMT (1.20 vs 0.90 mm, P < 0.001) and a 22.2% reduction in right CIMT (1.22 vs 0.95 mm, P < 0.001) 48. Another small prospective randomized study performed with 38 Japanese patients with chronic kidney disease showed that rosuvastatin 2.5 mg daily for 12 months significantly reduced maximal CIMT (1.89 vs 1.75 mm, P = 0.02) and modified the inflammatory state of these patients 49. A very recent study examined the effect of rosuvastatin on progression of atherosclerosis in 36 HIV-infected patients with asymptomatic carotid atherosclerosis and hypercholesterolemia who were on stable antiretroviral therapy 50.…”